Canopy Growth Corporation (CGC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.09. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is CGC = $14 (+1227.5% upside).
Valuation: CGC trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.15.
Financials: revenue is $267M, -19.6%/yr average growth. Net income is $595M (loss), growing at -281%/yr. Net profit margin is -222.4% (negative). Gross margin is 20.6% (+57.7 pp trend).
Balance sheet: total debt is $346M against $484M equity (Debt-to-Equity (D/E) ratio 0.72, moderate). Current ratio is 3.12 (strong liquidity). Debt-to-assets is 38%. Total assets: $912M.
Analyst outlook: 9 / 26 analysts rate CGC as buy (35%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 37/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).
